Sept. 29, 2016
Amgen and Arrowhead Pharmaceuticals Inc. have announced two license and collaboration agreements to develop and commercialize RNA interference (RNAi) therapies for cardiovascular disease. Under the first agreement, Amgen receives a worldwide, exclusive license to Arrowhead’s novel, RNAi ARC-LPA program. The RNAi molecules are designed to decrease elevated lipoprotein, which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. As per the second agreement, Amgen receives an option to a worldwide, exclusive license for a RNAi therapy for an undisclosed genetically validated cardiovascular target. Amgen will be wholly responsible for clinical development and commercialization in both agreements.
Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, said: “Arrowhead’s expertise in RNAi makes them a valuable partner as we translate genetic discoveries into potential therapies that can improve health outcomes for patients. This collaboration builds upon our commitment to cardiovascular disease with targets that we believe are uniquely suited for RNAi-based therapy.”
“We have made great advances to our proprietary subcutaneous RNAi delivery vehicle and in RNAi trigger modification and stabilization that enable rapid development of new RNAi therapeutics across multiple disease areas. Our capabilities and platform technologies are becoming increasingly validated, so we feel that now is a great time to expand the reach of our technologies and partner with other companies to maximize the value of our assets. We are thrilled to be working with Amgen, one of the world’s leading biotechnology companies, on this collaboration. Amgen’s extensive development, regulatory, and commercial expertise makes them an ideal partner, and we look forward to a long and productive relationship,” said Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead.Two Cardiovascular Collaborations Announced by Amgen and Arrowhead Pharmaceuticals last edit: 2016-10-18T16:41:23+00:00 da